Founding price: Foundation is $69 for the first 250 buyers or until 31 Dec 2026, whichever comes first, then $79. Free creatine tub with Foundation, code FIRST100, one per customer, first 100 Foundation orders.$69 founding price. Free extra creatine tub, one per customer, first 100 Foundation orders.
Learn

GLP-1 therapy and lean mass: what the trials actually measured

A share of the weight lost on GLP-1 medicines is lean mass. What the published numbers say, what they do not, and what preserves muscle during weight loss in general.

A 2026 systematic review and meta-analysis of randomised trials reported that, on incretin therapy for obesity, an estimated 25% to 39% of the weight lost was lean mass: semaglutide 35.2% (95% CI 31.5 to 38.9), tirzepatide 25.4% and liraglutide 26.8%.

Three caveats matter before drawing any conclusion from those percentages.

  • These are separate pooled estimates from heterogeneous studies, with wide heterogeneity (one analysis reported I2 = 98%), not a single head-to-head comparison.
  • Within that same review, lifestyle intervention alone was associated with 26.2% (p = 0.42, not statistically different from the incretin estimates) and lifestyle plus resistance training with 17.5%. These come from different study populations and must not be read as a direct comparison between drugs and training.
  • A separate analysis in Annals of Internal Medicine reported a median of 28.3% of weight lost from muscle-based measures (IQR 15.9 to 39.9) within the incretin groups, across agents and measurement methods; the lifestyle and placebo groups were analysed separately in that paper.

A further meta-analysis found that absolute lean mass fell by about 1.74 kg, but lean mass as a share of body weight rose by about 1.81 percentage points, so people ended the studies relatively leaner. (How DXA lean mass relates to muscle tissue needs full-text verification; this article makes no imaging claim.)

MeasureFigureSource
Share of weight lost as lean mass, semaglutide35.2% (95% CI 31.5 to 38.9)Systematic review, DOM 2026
Share of weight lost as lean mass, tirzepatide25.4%Systematic review, DOM 2026
Share of weight lost as lean mass, liraglutide26.8%Systematic review, DOM 2026
Lifestyle intervention alone26.2% (p = 0.42)Same review, separate populations
Lifestyle plus resistance training17.5%Same review, separate populations
Median share from muscle-based measures, incretin groups28.3% (IQR 15.9 to 39.9)Annals of Internal Medicine 2026
Absolute lean mass changeabout minus 1.74 kgMeta-analysis, Int J Obes 2026
Lean mass as share of body weightup about 1.81 pointsSame meta-analysis

What the supporting evidence covers

In the general adult and older-adult populations those trials studied, resistance training and adequate protein intake are both evidence-backed strategies associated with preserving lean mass during weight loss.

Morton and colleagues (British Journal of Sports Medicine, 2018, 49 randomised trials) found protein plus resistance training added about 0.30 kg of fat-free mass, with little additional benefit above about 1.6 g of protein per kg per day. Kim and colleagues (Nutrition Reviews, 2016) found adults over 50 on calorie restriction kept more lean mass at higher protein intakes.

Neither source studied GLP-1 users or whey specifically, so evidence in GLP-1 users is still emerging, and neither establishes a hierarchy between the two strategies. This article carries no whey-specific or convenience claim; product questions belong on the product pages with their label sourcing.

What the advisory highlights

The joint advisory from ACLM, ASN, OMA and TOS identifies nutritional priorities during GLP-1 therapy for obesity and recommends resistance training and appropriate dietary support to help preserve muscle and bone mass.

It does not give a protein gram figure or a full nutrient list in its abstract, so no number is quoted here; the full text would be needed before any numeric claim.

Who should be careful

Older adults: per Morton and colleagues, the protein-plus-training effect on fat-free mass shrinks with age. Readers with medical questions should consult a qualified clinician before changing diet, exercise or medicines. Nothing here advises starting or stopping a prescribed medicine. This is not medical advice.

Disclosure

Everstack sells a whey protein add-on and a multivitamin. No structure-function claim about either product appears in this article, because no substantiation for a product claim sits in the sources cited here; label-compliant claims live on the product pages only.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Not ready to buy yet?

A short email when there is something worth saying: the evidence we have graded, label changes, and new batches.

No health advice. Unsubscribe anytime. Privacy notice

Back to Learn

Sources

  1. Lean mass changes with incretin therapy versus lifestyle intervention: systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab, 2026. doi.org/10.1111/dom.70666
  2. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis. Int J Obes, 2026. doi.org/10.1038/s41366-026-02118-y
  3. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr, 2025. doi.org/10.1016/j.ajcnut.2025.04.023
  4. Effect of incretin-based and nonpharmacologic weight loss on body composition. Ann Intern Med, 2026. doi.org/10.7326/ANNALS-25-00478
  5. Morton et al., Br J Sports Med 2018. doi.org/10.1136/bjsports-2017-097608
  6. Kim et al., Nutr Rev 2016. doi.org/10.1093/nutrit/nuv065
  7. STEP 1, NEJM 2021. doi.org/10.1056/NEJMoa2032183
  8. SURMOUNT-1, NEJM 2022. doi.org/10.1056/NEJMoa2206038